Abstract
The FDA approved lenvatinib (Lenvima, Eisai Inc.) for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory (RAI-refractory) differentiated thyroid cancer (DTC). In an international, multicenter, double-blinded, placebo-controlled trial (E7080-G000-303), 392 patients with locally recurrent or metastatic RAI-refractory DTC and radiographic evidence of disease progression within 12 months prior to randomization were randomly allocated (2:1) to receive either lenvatinib 24 mg orally per day (n = 261) or matching placebo (n = 131) with the option for patients on the placebo arm to receive lenvatinib following independent radiologic confirmation of disease progression. A statistically significant prolongation of progression-free survival (PFS) as determined by independent radiology review was demonstrated [HR, 0.21; 95% confidence interval (CI), 0.16-0.28; P < 0.001, stratified log-rank test], with an estimated median PFS of 18.3 months (95% CI, 15.1, NR) in the lenvatinib arm and 3.6 months (95% CI, 2.2-3.7) in the placebo arm. The most common adverse reactions, in order of decreasing frequency, observed in the lenvatinib-treated patients were hypertension, fatigue, diarrhea, art...Continue Reading
Citations
Jul 2, 2016·Expert Review of Clinical Pharmacology·Athanasios BikasKenneth D Burman
Aug 27, 2016·Expert Opinion on Drug Metabolism & Toxicology·Andrew RowlandMichael J Sorich
Nov 5, 2016·International Journal of Pharmaceutics·Adam C FisherJanet Woodcock
Mar 27, 2018·Cancer Cytopathology·Amber L SmithSinchita Roy-Chowdhuri
May 9, 2018·Expert Review of Anticancer Therapy·Hana ŠtudentováBohuslav Melichar
Sep 19, 2017·Expert Opinion on Drug Safety·E GrandeJ Larkin
Apr 25, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yuji Eso, Hiroyuki Marusawa
Jan 20, 2018·Endocrine-related Cancer·Sara RedaelliLuca Mologni
Jul 20, 2019·Thyroid : Official Journal of the American Thyroid Association·Leila ShobabKenneth D Burman
Oct 15, 2019·Expert Opinion on Drug Discovery·Rosa Maria ParagliolaSalvatore Maria Corsello
Jan 15, 2020·Health Technology Assessment : HTA·Nigel FleemanAditya Shenoy
Oct 16, 2019·The Oncologist·Zhonglin Hao, Peng Wang
Sep 4, 2019·Therapeutic Drug Monitoring·Evelina CardosoNicolas Widmer
Jun 23, 2016·Oncotarget·Chenjing ZhuYue Xiao
Nov 17, 2017·The Journal of Pathology·Jialong LiangZhong Sheng Sun
Jul 28, 2018·Journal of the National Cancer Institute·Moran AmitZiv Gil
Jan 9, 2019·Frontiers in Endocrinology·Silvia Martina FerrariAlessandro Antonelli
Mar 25, 2017·Drugs·Stefan MichielsMarc Buyse
Feb 2, 2019·Current Vascular Pharmacology·Cecilie BudolfsenNils Erik Magnusson
Sep 14, 2017·Molecular Medicine Reports·Jia LiXiu-Ju Chen
May 20, 2019·World Journal of Surgical Oncology·Nai-Wei SheuPi-Jung Hsiao
Jan 1, 2021·Case Reports in Hepatology·Katsutoshi Ishihara
Jan 21, 2021·Cancers·Freba AhmaddyAndrei Todica
Feb 19, 2021·Frontiers in Endocrinology·Rachael WybrewLeslie Samuel
Feb 12, 2020·The Oncologist·Zhonglin Hao, Peng Wang
Apr 30, 2021·British Journal of Cancer·Maria M RubinsteinNeil M Iyengar
Apr 10, 2021·Clinical Endocrinology·Zhipeng YanChing-Lung Lai
Jul 23, 2021·Expert Review of Clinical Pharmacology·Martina CatalanoGiandomenico Roviello
Aug 25, 2021·Expert Opinion on Investigational Drugs·Silvia Martina FerrariPoupak Fallahi
Oct 5, 2021·Frontiers in Endocrinology·Tong WuAnkui Yang